BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//6.4.7.2//EN
TZID:Europe/Paris
X-WR-TIMEZONE:Europe/Paris
BEGIN:VEVENT
UID:0-1009@lptms.universite-paris-saclay.fr
DTSTART;TZID=Europe/Paris:20250627T110000
DTEND;TZID=Europe/Paris:20250627T120000
DTSTAMP:20250306T165929Z
URL:http://www.lptms.universite-paris-saclay.fr/seminars/physics-biology-i
 nterface-seminar-simona-mura/
SUMMARY:Physics-Biology Interface seminar: Simona Mura - Salle des séminai
 res du FAST et du LPTMS\, bâtiment Pascal n°530 - 27 Juin 25 11:00
DESCRIPTION:Breaking barriers: nanomedicine fate from administration target
  site\nS. Mura\, Orsay/France\nNanoscale systems for drug delivery have th
 e potential to overcome the limitations of conventional treatments\, thus 
 providing a solution to unmet medical needs.\nThe therapeutic benefits of 
 this approach have led to the commercialization of more than 50 nanomedici
 nes such as doxorubicin-loaded liposomes (Doxil®\, Myocet®)\, paclitaxel
 -albumin nanoparticles (Abraxane®)\, and more recently\, lipid carriers f
 or the delivery of siRNA (Patisiran/ONPATTRO®) or mRNA (BioNTech/Pfizer a
 nd Moderna COVID-19 vaccines).\nAlthough these results provide clear evide
 nce of the potential of nanomedicines for the efficient delivery of chemot
 herapeutics\, there is still a substantial gap between the favorable precl
 inical results and the real clinical performances.\nThe introduction of na
 nomedicine in the clinic has been partly hampered by the lack of effective
  delivery to the target in vivo. Among the multiplicity of imputable facto
 rs\, a major role can be attributed to: (i) the modifications undergone by
  nanomedicines after interaction with molecules/proteins in the bloodstrea
 m that endow them with a specific molecular signature and (ii) the numerou
 s biological barriers that these nanomedicines must cross (e.g.\, the vasc
 ular endothelium\, the tumor extracellular matrix\, etc…). \nIn this con
 text\, it is necessary to have a clearer comprehension of their fate after
  administration.\nOur research group is focusing on this topic\, and we ar
 e developing different tools to investigate and better understand the barr
 iers encountered nanomedicines both in the circulation after intravenous a
 dministration and\, after extravasation\, in the complex tumor microenviro
 nment.\nDuring this talk\, the most significant results we have obtained w
 ill be presented\nLiterature:\n[1] Sobot D\, Mura S\, Yesylevskyy SO\, Dal
 bin L\, Cayre F\, Bort G\, Mougin J\, Desmaële D\, Lepetre-Mouelhi S\, Pi
 eters G\, Andreiuk B\, Klymchenko AS\, Paul JL\, Ramseyer C\, Couvreur P. 
 Nature Comm 2017\, 8\, 15678 \n[2] Lazzari G\, Nicolas V\, Matsusaki M\, A
 kashi M\, Couvreur P\, Mura S. Acta Biomaterialia 2018\, 78\, 296.\n[3] Bi
 dan N\, Dunsmore G\, Ugrinic M\, Bied M\, Moreira M\, Deloménie C\, Ginho
 ux F\, Blériot C\, de la Fuente M\, Mura S. Drug Deliv Transl Res. 2023
CATEGORIES:physbio,seminars
LOCATION:Salle des séminaires du FAST et du LPTMS\, bâtiment Pascal n°53
 0\, rue André Riviere\, Orsay\, 91405\, France
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=rue André Riviere\, Orsay\
 , 91405\, France;X-APPLE-RADIUS=100;X-TITLE=Salle des séminaires du FAST 
 et du LPTMS\, bâtiment Pascal n°530:geo:0,0
END:VEVENT
BEGIN:VTIMEZONE
TZID:Europe/Paris
X-LIC-LOCATION:Europe/Paris
BEGIN:DAYLIGHT
DTSTART:20250330T030000
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
END:DAYLIGHT
END:VTIMEZONE
END:VCALENDAR